Health & Bio2 min read
Health & Bio
Ultragenyx's Angelman Syndrome Drug Fails Late-Stage Trial
Ultragenyx said its experimental Angelman syndrome drug, GTX-102, showed no benefit over a sham treatment in a large Phase 3 trial, dashing hopes raised by strong earlier results.
Ultragenyx said Wednesday that its experimental therapy for Angelman syndrome, a rare genetic disease that causes severe intellectual disability and developmental delays, showed no benefit over a in a large late-stage clinical trial.
The drug, called GTX-102, had shown strong results in earlier, smaller trials, raising hopes among families affected by the condition. Advocates for patients with other neurological and intellectual disability conditions had also hoped it could become the first of a new generation of medicines to improve cognition and communication for such patients.
The failed trial is also a setback for Ultragenyx's business. The company already sells several approved medicines, but these treat mostly ultra-rare diseases, and investors had been counting on the Angelman drug to be its path to profitability.
Terms explained
The story so far
- Blood Thinners Cut Major Complications by 69% in Atrial Fibrillation Trial
- Scientists Find a Way to Weaken Pancreatic Cancer's Protective Shield
- AstraZeneca's Breast Cancer Pill Fails Key Trial as First-Line Therapy
- FDA Approves First Drug to Target Muscle Loss in Spinal Muscular Atrophy
- Zipalertinib Plus Chemotherapy Nearly Doubles Progression-Free Time in Lung Cancer Trial
- Definium's LSD Therapy Eases Anxiety in Second Late-Stage Trial
- Ultragenyx's Angelman Syndrome Drug Fails Late-Stage Trial
#Ultragenyx#Angelman syndrome#clinical trial#rare disease#biotech
Rate this story